ELECTRONIC BIOSCIENCES, INC. — Department of Health and Human Services SBIR Phase I: 101

Description

DESCRIPTION provided by applicant Due to the growing number of therapeutic uses for botulinum neurotoxin BoNT within the medical and cosmetic industries new characterization techniques are currently needed to assess toxin activity e g potency for accurate dose administration BoNT potency is currently assessed using a mouse intraperitoneal injection assay also known as the mLD assay which is based on the rate at which a population of mice is euthanized upon exposure to BoNT Not only does this assay require the use of vertebrate animals conflicting with current FDA and NIH guidelines it is also lengthy and has high variability The mLD assay takes to days and yields high error rates due to variations in mouse sensitivity and test conditions Electronic BioSciences Inc EBS which specializes in combining biological systems with high performance electronics for sensing applications proposes to develop an in vitro alternative to the mLD assay This proposed low cost assay will be highly sensitive and capable of quickly characterizing the complete BoNT mechanism thus providing insight into the toxin mode of activity not currently possible PUBLIC HEALTH RELEVANCE The proposed system is being developed as a commercial alternative to the mouse intraperitoneal injection assay to enable complete potency characterization of botulinum neurotoxin Type A BoNT A therapeutics during production BoNT A is used in numerous medical treatments today with its use expanding each year and the accurate characterization of its potency is critical to patient safety The benefits of the proposed system include reducing assay costs and testing times improving the accuracy of the assay and aligning with NIH and FDA guidelines for reducing the use of vertebrate animals for assays of biological activity